The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer
Open accessAbstract
In this study, we quantified 249 mature micro-RNA (miRNA) transcripts in estrogen receptor-positive (ER+) primary breast tumors of patients with lymph node-negative (LNN) disease to identify miRNAs associated with metastatic capability. In addition, the prognostic value of the candidate miRNAs was determined in ER−/LNN breast cancer. Unsupervised analysis in a prescreening set of 38 patients identified three subgroups predominantly driven by three miRNA signatures: an ER-driven luminal B-associated miRNA signature, a stromal miRNA signature, and an overexpressed miRNA cluster located on chromosome 19q23, but these intrinsic miRNA signatures were not associated with tumor aggressiveness. Supervised analysis in the initial subset and subsequent analysis in additional tumors significantly linked four miRNAs (miR-7,miR-128a,miR-210, and miR-516–3p) to ER+/LNN breast cancer aggressiveness (n= 147) and one miRNA (miR-210) to metastatic capability in ER−/LNN breast cancer (n= 114) and in the clinically important triple-negative subgroup (n= 69) (all P< 0.05). Bioinformatic analysis coupled miR-210 to hypoxia/VEGF signaling,miR-7 and miR-516–3p to cell cycle progression and chromosomal instability, and miR-128a to cytokine signaling. In conclusion, our work connects four miRNAs to breast cancer progression and to several distinct biological processes involved therein.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Bartel (2004) · doi:10.1016/s0092-8674(04)00045-5 · Cited by 34,714
Vandesompele, J., De Preter, K., Pattyn, F., Poppe, B., Van Roy, N., De Paepe, A., & Speleman, F. (2002) · Genome Biology · doi:10.1186/gb-2002-3-7-research0034 · Cited by 20,038
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Gene expression profiling predicts clinical outcome of breast cancer
van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536
MicroRNA signatures in human cancers
Calin, G. A., & Croce, C. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1997 · Cited by 7,590
Andersen, C. L., Jensen, J. L., & Ørntoft, T. F. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0496 · Cited by 7,127
Cox, D. R., & Oakes, D. (2018) · Chapman & Hall/CRC eBooks · doi:10.1201/9781315137438 · Cited by 6,234
A microRNA expression signature of human solid tumors defines cancer gene targets
Volinia, S., Calin, G. A., Liu, C.-G., Ambs, S., Cimmino, A., Petrocca, F., Visone, R., Iorio, M., Roldo, C., Ferracin, M., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510565103 · Cited by 5,697
Cited by
Farazi, T. A., Spitzer, J. I., Morozov, P., & Tuschl, T. (2011) · The Journal of Pathology · doi:10.1002/path.2806 · Cited by 895
Bertoli, G., Cava, C., & Castiglioni, I. (2015) · Theranostics · doi:10.7150/thno.11543 · Cited by 815
Farazi, T. A., Hoell, J. I., Morozov, P., & Tuschl, T. (2013) · Advances in Experimental Medicine and Biology · doi:10.1007/978-94-007-5590-1_1 · Cited by 693
Hypoxia-Inducible mir-210 Regulates Normoxic Gene Expression Involved in Tumor Initiation
Huang, X., Ding, L., Bennewith, K. L., Tong, R. T., Welford, S. M., Ang, K. K., Story, M., Le, Q.-T., & Giaccia, A. J. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.09.006 · Cited by 617
MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers
Seike, M., Goto, A., Okano, T., Bowman, E. D., Schetter, A. J., Horikawa, I., Mathe, E. A., Jen, J., Yang, P., Sugimura, H., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905234106 · Cited by 500
Prognostic and predictive biomarkers in breast cancer: Past, present and future
Nicolini, A., Ferrari, P., & Duffy, M. J. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.08.010 · Cited by 424
Puisségur, M.-P., Mazure, N. M., Bertero, T., Pradelli, L., Grosso, S., Robbe-Sermesant, K., Maurin, T., Lebrigand, K., Cardinaud, B., Hofman, V, et al. (2011) · Cell Death & Differentiation · doi:10.1038/cdd.2010.119 · Cited by 423
Detection of Cancer with Serum miRNAs on an Oligonucleotide Microarray
Lodes, M. J., Caraballo, M., Suciu, D., Munro, S., Kumar, A., & Anderson, B. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006229 · Cited by 406
Prioritization of disease microRNAs through a human phenome-microRNAome network
Jiang, Q., Hao, Y., Wang, G., Juan, L., Zhang, T., Teng, M., Liu, Y., & Wang, Y. (2010) · BMC Systems Biology · doi:10.1186/1752-0509-4-s1-s2 · Cited by 389
Plasma microRNAs as potential biomarkers for non-small-cell lung cancer
Shen, J., Todd, N. W., Zhang, H., Yu, L., Lingxiao, X., Mei, Y., Guarnera, M., Liao, J., Chou, A., Lu, C. L., et al. (2011) · Laboratory Investigation · doi:10.1038/labinvest.2010.194 · Cited by 383
MiR-210 – micromanager of the hypoxia pathway
Huang, X., Le, Q.-T., & Giaccia, A. J. (2010) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.03.004 · Cited by 376
Zhang, H., Cai, K., Wang, J., Wang, X., Cheng, K., Shi, F., Jiang, L., Zhang, Y., & Dou, J. (2014) · Stem Cells · doi:10.1002/stem.1795 · Cited by 368
Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA
Volinia, S., Galasso, M., Sana, M. E., Wise, T. F., Palatini, J., Huebner, K., & Croce, C. M. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1200010109 · Cited by 359
MicroRNA-210: A unique and pleiotropic hypoxamir
Chan, S. Y., & Loscalzo, J. (2010) · Cell Cycle · doi:10.4161/cc.9.6.11006 · Cited by 357
MicroRNA Sequence and Expression Analysis in Breast Tumors by Deep Sequencing
Farazi, T. A., Horlings, H. M., ten Hoeve, J. J., Mihailovic, A., Halfwerk, H., Morozov, P., Brown, M., Hafner, M., Reyal, F., van Kouwenhove, M., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0608 · Cited by 346
Rao, X., Di Leva, G., Li, M., Fang, F., Devlin, C., Hartman-Frey, C., Burow, M. E., Ivan, M., Croce, C. M., & Nephew, K. P. (2011) · Oncogene · doi:10.1038/onc.2010.487 · Cited by 342
miRNA-mRNA Integrated Analysis Reveals Roles for miRNAs in Primary Breast Tumors
Enerly, E., Steinfeld, I., Kleivi, K., Leivonen, S.-K., Aure, M. R., Russnes, H. G., Rønneberg, J. A., Johnsen, H., Navon, R., Rødland, E., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016915 · Cited by 310
Buffa, F. M., Camps, C., Winchester, L., Snell, C. E., Gee, H. E., Sheldon, H., Taylor, M., Harris, A. L., & Ragoussis, J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0489 · Cited by 308
Small nucleolar RNA signatures as biomarkers for non-small-cell lung cancer
Liao, J., Yu, L., Mei, Y., Guarnera, M., Shen, J., Li, R., Liu, Z., & Jiang, F. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-198 · Cited by 293
Jung, E., Santarpia, L., Kim, J., Esteva, F. J., Moretti, E., Buzdar, A. U., Di Leo, A., Le, X., Bast, R. C., Park, S., et al. (2012) · Cancer · doi:10.1002/cncr.26565 · Cited by 292
miR‐210: More than a silent player in hypoxia
Devlin, C., Greco, S., Martelli, F., & Ivan, M. (2011) · IUBMB Life · doi:10.1002/iub.427 · Cited by 289
miR-7 Suppresses Brain Metastasis of Breast Cancer Stem-Like Cells By Modulating KLF4
Okuda, H., Xing, F., Pandey, P. R., Sharma, S., Watabe, M., Pai, S. K., Mo, Y.-Y., Iiizumi-Gairani, M., Hirota, S., Liu, Y., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2037 · Cited by 285
Identification of Circulating MicroRNA Signatures for Breast Cancer Detection
Chan, M., Liaw, C. S., Ji, S. M., Tan, H. H., Wong, C. Y., Thike, A. A., Tan, P. H., Ho, G. H., & Lee, A. S.-G. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3401 · Cited by 274
Keklikoglou, I., Koerner, C., Schmidt, C., Zhang, J. D., Heckmann, D., Shavinskaya, A., Allgayer, H., Gückel, B., Fehm, T., Schneeweiss, A., et al. (2012) · Oncogene · doi:10.1038/onc.2011.571 · Cited by 273
Chou, Y.-T., Lin, H.-H., Lien, Y.-C., Wang, Y.-H., Hong, C.-F., Kao, Y.-R., Lin, S.-C., Chang, Y.-C., Lin, S.-Y., Chen, S.-J., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0638 · Cited by 270
An Integrated Approach for Experimental Target Identification of Hypoxia-induced miR-210
Fasanaro, P., Greco, S., Lorenzi, M., Pescatori, M., Brioschi, M., Kulshreshtha, R., Banfi, C., Stubbs, A., Calin, G. A., Ivan, M., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.052779 · Cited by 268
Spizzo, R., Nicoloso, M. S., Lupini, L., Lu, Y., Fogarty, J., Rossi, S., Zagatti, B., Fabbri, M., Veronese, A., Liu, X., et al. (2010) · Cell Death & Differentiation · doi:10.1038/cdd.2009.117 · Cited by 258
García-Becerra, R., Santos, N., Díaz, L., & Camacho, J. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms14010108 · Cited by 253
Honegger, A., Schilling, D., Bastian, S., Sponagel, J., Kuryshev, V., Sültmann, H., Scheffner, M., Hoppe-Seyler, K., & Hoppe-Seyler, F. (2015) · PLOS Pathogens · doi:10.1371/journal.ppat.1004712 · Cited by 222
Adlakha, Y. K., & Saini, N. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-33 · Cited by 213
Estrogen Regulation of MicroRNA Expression
Klinge, C. (2009) · Current Genomics · doi:10.2174/138920209788185289 · Cited by 156
The circular RNome of primary breast cancer
Smid, M., Wilting, S. M., Uhr, K., Rodríguez-González, F. G., de Weerd, V., Prager-Van der Smissen, W. J. C., van der Vlugt-Daane, M., van Galen, A., Nik-Zainal, S., Butler, A., et al. (2019) · Genome Research · doi:10.1101/gr.238121.118 · Cited by 105
Self-citationA microRNA Signature Associated with Early Recurrence in Breast Cancer
Pérez-Rivas, L. G., Jerez, J. M., Carmona, R., de Luque, V., Vicioso, L., Claros, M. G., Viguera, E., Pajares, B., Sánchez, A., Ribelles, N., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0091884 · Cited by 67
Analysis of miRNA expression profiles in breast cancer using biclustering
Fiannaca, A., La Rosa, M., La Paglia, L., Rizzo, R., & Urso, A. (2015) · BMC Bioinformatics · doi:10.1186/1471-2105-16-s4-s7 · Cited by 45
Huang, Q., Yang, J., Zheng, J., Hsueh, C., Guo, Y., & Zhou, L. (2018) · Oncology Reports · doi:10.3892/or.2018.6672 · Cited by 19
HypoxaMIRs: Key Regulators of Hallmarks of Colorectal Cancer
Coronel-Hernández, J., Delgado-Waldo, I., Cantú de León, D., López-Camarillo, C., Jacobo-Herrera, N., Ramos-Payán, R., & Pérez-Plasencia, C. (2022) · Cells · doi:10.3390/cells11121895 · Cited by 13
“In breast cancer, mir-210 expression is considered a biomarker of cancer progression, with a direct correlation to metastatic capability [63,64].”
Background
Metadata
- Authors
- Foekens, J. A., Sieuwerts, A. M., Smid, M., Look, M. P., de Weerd, V., Boersma, A. W. M., Klijn, J. G. M., Wiemer, E. A. C., & Martens, J. W. M.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2008-09-02
- Volume
- 105
- Issue
- 35
- Pages
- 13021-13026
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2149992636
- Cited by
- 370
- References
- 41
- FWCI
- 10.92
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.